⁕PathSensors was acquired by Smiths Detection on August 4th, 2020⁕
PathSensors Inc., a Baltimore biotechnology company, announced today that Massachusetts Institute of Technology (MIT) has expanded the company’s exclusive license to include clinical applications for CANARY™ technology. This broader license allows PathSensors to move into the point-of-care diagnostic market, focusing initially on the SARS-CoV-2 biosensor. CANARY’s™ fast and highly sensitive assays will help to address the shortage of COVID-19 testing capabilities in the United States.
The company’s core business is environmental testing in fields such as building protection, mail security, food safety, and agriculture. Test panels for other infectious diseases will follow in future years.
“PathSensors originally developed CANARY™ technology for commercial use in 2012,” stated PathSensors’ President, Ted Olsen. “Now 8 years later, we are bringing CANARY™ to the healthcare field to provide rapid and highly sensitive detection solutions for a major public health crisis.”
CANARY™ is a biosensor technology that delivers extremely rapid detection of pathogens with high sensitivity and specificity. Originally developed by scientists at MIT–Lincoln Laboratory to combat bioterrorism threats, CANARY™ has been licensed and commercialized by PathSensors, Inc.